North Star Investment Management’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6
| Closed | -$174 | – | 1762 |
|
|
2025
Q4 | $174 | Hold |
6
| – | – | ﹤0.01% | 1552 |
|
|
2025
Q3 | $47 | Hold |
6
| – | – | ﹤0.01% | 1306 |
|
|
2025
Q2 | $44 | Hold |
6
| – | – | ﹤0.01% | 1201 |
|
|
2025
Q1 | $52 | Hold |
6
| – | – | ﹤0.01% | 1186 |
|
|
2024
Q4 | $214 | Hold |
6
| – | – | ﹤0.01% | 1185 |
|
|
2024
Q3 | $284 | Hold |
6
| – | – | ﹤0.01% | 1146 |
|
|
2024
Q2 | $302 | Hold |
6
| – | – | ﹤0.01% | 1122 |
|
|
2024
Q1 | $672 | Hold |
6
| – | – | ﹤0.01% | 1171 |
|
|
2023
Q4 | $348 | Hold |
6
| – | – | ﹤0.01% | 1150 |
|
|
2023
Q3 | $190 | Hold |
6
| – | – | ﹤0.01% | 1243 |
|
|
2023
Q2 | $494 | Hold |
6
| – | – | ﹤0.01% | 1215 |
|
|
2023
Q1 | $616 | Hold |
6
| – | – | ﹤0.01% | 1220 |
|
|
2022
Q4 | $879 | Hold |
6
| – | – | ﹤0.01% | 1183 |
|
|
2022
Q3 | $1K | Hold |
6
| – | – | ﹤0.01% | 1084 |
|
|
2022
Q2 | $1K | Hold |
6
| – | – | ﹤0.01% | 1088 |
|
|
2022
Q1 | $1K | Hold |
6
| – | – | ﹤0.01% | 1106 |
|
|
2021
Q4 | $1K | Hold |
6
| – | – | ﹤0.01% | 1134 |
|
|
2021
Q3 | $1K | Buy |
+6
| New | +$1.75K | ﹤0.01% | 1083 |
|
Other funds holding MRSN
North Star Investment Management's MRSN Position: Q1 2026 in Review
North Star Investment Management sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 6 shares — an estimated $174 sold.
North Star Investment Management first reported a position in MRSN in Q3 2021 and held it in 18 quarters. The position peaked at $1K in Q3 2022. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.
- North Star Investment Management reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
- North Star Investment Management sold 6 Mersana Therapeutics shares in Q1 2026, an estimated $174.
- North Star Investment Management first reported a position in Mersana Therapeutics in Q3 2021 and held it in 18 quarters.
- North Star Investment Management's Mersana Therapeutics position peaked at $1K in Q3 2022.
- 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.
Based on North Star Investment Management's 13F filing for Q1 2026, filed 23 Apr 2026.